The Infectious Diseases Society of America (IDSA) released updated guidelines on October 17, 2025, recommending immediate and prioritized COVID-19 vaccination for immunocompromised individuals. The guidelines highlight that over 40 million Americans with weakened immune systems remain at heightened risk of severe COVID-19 illness despite widespread vaccine availability. GeoVax Labs, Inc. (Nasdaq: GOVX) today welcomed the guidance, noting that it underscores the significant unmet need in this population and validates the company's approach with its investigational vaccine candidate, GEO-CM04S1.
According to the IDSA guidance, current COVID-19 vaccines offer moderate protection in immunocompromised patients, with effectiveness against hospitalization ranging from 33% to 56% and reduced protection against critical illness and mortality. The guidelines also note that immune responses remain attenuated and short-lived, with most studies showing waning effectiveness within two months of vaccination. This confirms what clinicians, patients, and policymakers have long recognized: existing vaccines are insufficient for the immunocompromised population.
GeoVax's GEO-CM04S1 is a multi-antigen, Modified Vaccinia Ankara (MVA)-based COVID-19 vaccine designed to stimulate both humoral (antibody) and cellular (T-cell) immunity. This broader immune activation is particularly important for immunocompromised patients, such as those undergoing chemotherapy, solid organ transplant, or receiving immunosuppressive biologics, who often fail to mount adequate antibody responses from current mRNA vaccines. "Unlike existing vaccines that rely primarily on antibody responses, GEO-CM04S1's multi-antigen design and proven MVA platform provide robust T-cell immunity, which is less affected by immunosuppressive conditions," said David A. Dodd, Chairman & CEO of GeoVax.
GEO-CM04S1 is currently being evaluated in multiple clinical studies among immunocompromised patients, including a Phase 2 trial in chronic lymphocytic leukemia (CLL) patients and a Phase 2 study in hematopoietic stem cell transplant recipients, both in direct comparison to mRNA vaccines. Interim results have demonstrated durable T-cell responses, sustained neutralizing activity across emerging variants, and favorable tolerability. Notably, in the CLL study, the mRNA vaccine arm was halted after not attaining the pre-determined continuation endpoint, while GEO-CM04S1 exceeded the endpoint, resulting in the remainder of the study being conducted only among GEO-CM04S1 recipients.
The IDSA panel emphasized that current vaccines—predominantly mRNA-based—provide incomplete and waning protection for immunocompromised individuals, especially transplant recipients and those receiving B-cell depleting therapies. GEO-CM04S1's structural design offers multi-antigen breadth (Spike + Nucleocapsid proteins), durable cellular immunity critical for long-term protection, and applicability across immunocompromised subgroups where antibody-only constructs appear inadequate. "IDSA's updated guidance validates the path GeoVax has taken," added Dodd. "By focusing on the needs of the over 40 million immunocompromised Americans and over 400 million worldwide, GEO-CM04S1 has the potential to fill one of the largest remaining gaps in COVID-19 protection."
GeoVax is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. More information about the company and its clinical trials can be found at www.geovax.com.
